Nedaplatin

SKU: orb1305527

Description

Nedaplatin (NSC-375101D) is a cisplatin-derived antineoplastic agent that forms DNA cross-links, inducing apoptosis. It is applied in oncology research, particularly for studying platinum-based chemotherapy mechanisms, and has demonstrated efficacy in both in vitro cytotoxicity assays and in vivo tumor model studies.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 95734-82-0
• MW: 303.17
• Purity: >99.99% (May vary between batches)
• Formula: C₂H₈N₂O₃Pt
• SMILES: N.N.[Pt++].[O-]CC([O-])=O
• Target: DNA/RNA Synthesis
• Solubility: H2O:10 mM;DMSO:Insoluble

Bioactivity

• Target IC50:
  DNA damage:94 μM
• In Vivo:
  Nedaplatin (Aqupla), a derivative of cisplatin, inhibits tumor clonogenic colony formation with an IC50 of 28.5 μg/mL. At concentrations ranging from 0.005 to 0.5 μg/mL, Nedaplatin suppresses the proliferation of SBC-3 cells by 2% to 98%, with an IC50 of 0.053 μg/mL.
• In Vitro:
  Compared to the use of each of the three drugs individually, pre-treating with 5-FU continuously before Nedaplatin or Cisplatin (FN or FC treatment) demonstrates a synergistic enhancement in inhibiting tumor growth and extending survival time.
• Cell Research:
  The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, cells are exposed to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; the cells are then pipetted six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The IC50 is defined as the drug concentration required for a 50% reduction in the number of cells. Four or five independent experiments are carried out for each. To check the effect of the drug treatment schedule on the effect of the combination, the cells are treated either by simultaneous exposure to the two drugs or by sequential exposure to Nedaplatin followed by irinotecan (Nedaplatin→irinotecan) and vice versa (irinotecan→Nedaplatin) for 3 hours. For the sequential exposure treatment, cells are exposed to the first drug for 3 hours, ished in fresh medium once, and then immediately exposed to the second drug for 3 hours. The treated cells are cultured in drug-free medium until evaluation.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DNA/RNA Synthesis, DNA Synthesis, DNA synthesis, DNASynthesis, Inhibitor, NSC 375101D, inhibit, Nedaplatin, RNA Synthesis, RNASynthesis

Compound Identifiers

PubChem CID

9796440